Table 4.
Plasma metabolites significantly associated with 25(OH)D concentrations common to age 1 and 3 samples based on ENT80 thresholds 1 after excluding outliers in 25(OH)D distribution at respective time points.
| Metabolite | Pathway | Age 1 Result 2 | Age 3 Result 3 | ||||
|---|---|---|---|---|---|---|---|
| P-Value | 95% CI | P-Value | 95% CI | ||||
| N-acetyltaurine | Methionine, Cysteine, SAM and Taurine Metabolism | −1.90 | 7.01 × 10−6 | (−2.72, −1.08) | −1.37 | 4.05 × 10−4 | (−2.13, −0.62) |
| docosapentaenoate (n-6 DPA; 22:5) | Long Chain PUFA | −1.91 | 1.29 × 10−5 | (−2.77, −1.06) | −1.40 | 4.28 × 10−4 | (−2.17, −0.62) |
| dihomo-linolenate (20:3 n-3 or n-6) | Long Chain PUFA | −1.88 | 1.60 × 10−5 | (−2.72, −1.03) | −1.33 | 8.10 × 10−4 | (−2.11, −0.56) |
| glycine | Glycine, Serine and Threonine Metabolism | −1.64 | 1.05 × 10−4 | (−2.46, −0.82) | −1.38 | 3.67 × 10−4 | (−2.13, −0.62) |
| arachidonate (20:4 n-6) | Long Chain PUFA | −1.62 | 1.13 × 10−4 | (−2.44, −0.80) | −1.34 | 6.58 × 10−4 | (−2.12, −0.57) |
| linoleate (18:2 n-6) | Long Chain PUFA | −1.56 | 1.79 × 10−4 | (−2.37, −0.75) | −1.63 | 3.14 × 10−5 | (−2.39, −0.87) |
| serine | Glycine, Serine and Threonine Metabolism | −1.59 | 1.87 × 10−4 | (−2.41, −0.76) | −1.30 | 7.74 × 10−4 | (−2.05, −0.55) |
| N-palmitoylglycine | Fatty Acid Metabolism (Acyl Glycine) | −1.50 | 4.28 × 10−4 | (−2.34, −0.67) | −1.65 | 2.21 × 10−5 | (−2.40, −0.89) |
| 1-palmitoyl-GPE (16:0) | Lysophospholipid | −1.47 | 5.11 × 10−4 | (−2.29, −0.64) | −1.53 | 8.81 × 10−5 | (−2.28, −0.77) |
| linoleoyl ethanolamide | Endocannabinoid | −1.43 | 6.57 × 10−4 | (−2.25, −0.61) | −1.29 | 9.53 × 10−4 | (−2.06, −0.53) |
| valylglycine | Dipeptide | −1.44 | 6.59 × 10−4 | (−2.26, −0.61) | −1.81 | 4.43 × 10−6 | (−2.57, −1.04) |
1 The P-value thresholds for declaring significance were 8.27 × 10−4 in age 1 analysis and 9.67 × 10−4 in age 3 analysis. 2,3 Linear models adjusted for sex, race, ethnicity, study site, BMI at respective age, season of blood collection, and asthma or recurrent wheezing status by age 3. Abbreviations: , estimated effect; CI, confidence interval; ENT, effective number of independent tests; GPE, glycerophosphoethanolamine; PUFA, polyunsaturated fatty acid; SAM, S-adenosyl methionine; 25(OH)D, 25-hydroxyvitamin D.